Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.
After years of optimism regarding IMM, I've finally sold out at a 97% loss in my investment. Incredibly disappointing to see what's happening for long term holders but especially more so for the sufferers.
How could a company get it so wrong???? Oh, I've just remembered, Tim McC is in charge....
Good luck to all LTH's here and Lupus sufferers.
Hi Dh2133, Can you ask if IMM are getting any positive feedback already from the follow on trial? Has there been any encouraging feedback from the regulatory bodies (FDA, etc) so far? I suspect you won't get answers to some of the questions but the body language will be interesting. Many thanks!
Entirely possible this news has been released to put some pressure on any potential partners to put up or shut up. Wouldn’t surprise me if we see a few more encouraging result RNS’s over the coming weeks.
Yes, Elegance. I hope some interesting statistics come up of the data analysis. What happens, for example, if Mauritian trial participants skewed the trial results strongly on the placebo side? It would certainly back up the bull argument that the test failed, not the drug. I don�t expect the FDA to sign Lupozor off without there being some conditions attached. But it won�t be dismissed out of hand like some of the bears want it to be.
I just can't see IMM accepting an offer below £1.50. There are a lot of share options floating around at that level and Simbec-Orion will be wanting to make a profit out of their shareholding. I appreciate that IMM is only worth what a suitor is prepared to pay but with over 10 companies sniffing around I hope Bryan Garnier will be able to initiate a bidding war...
Why do you suggest that IPad?
Apologies, that should have been degsy, not degustation!!!!
Degustation, there�s certainly a lot more to come out I hope about the placebo effect once more analysis is done. Don�t entirely know how true it isn�t but someone mentioned that if the placebo effect had been lower we�d have met statistical significance. But placebo was far, far higher than anyone was expecting. I�m certainly hoping we see a marked placebo effect from Mauritius. And I also hope the FDA keep an open mind about the results if the high placebo result can be explained sufficiently.
What I�m unclear about is if SOC is also included with Lupozor on the follow on trial. Whilst riskier if it is just Lupozor and it proves not to work then it�s game over for IMM unless they�ve concluded a takeover or partnership before the OLE results are released. Are results analysed through the trial or only at the end?
I�m hoping this kind of question will get answered once more data analysis happens. Tim thought a high placebo effect was the greatest danger so I�d expect that a placebo effect analysis by region would be a necessity for negotiations with regulators and potential partners.
The new FDA approach is critical to determining how this progresses for patients and shareholders alike. If we get encouraging signs then it can only strengthen IMM�s position in negotiations along with bolstering the share price, improving future returns and a faster route to market for Lupozor. All to play for despite what the naysayers say!
Great questions to Nolupus by the way.
Yes, the top level results definitely can't be classified as black or white. There are positives in there so further analysis of the data will be very insightful. Only black in all of this is not meeting statistical significance and the stupidity of IMM for not running a larger trial. The white to me is the dropout rate as that would skew the results. GLA LTH's!
I've been of the opinion for quite a while that freedom of movement doesn't need to be full access to a country and it's benefits. What is so wrong with only allowing people in if they have a job to come to? I could see this approach being quite acceptable to a host of EU member states and would be a good compromise position. If Hollande, Merkel, Juncker and friends insist on no internal controls then it's going to hasten the end of the EU experiment....
Positive news for Quindell shareholders but worrying for us shareholders in ANY company if it's not a prosecutable offence to mislead auditors. Just encouraging more GLOBO's then.....
A very frustrating share this one. I'd have expected this to have stayed around the 460-470p area. It almost warrants short term dealing as a way of increasing your shares held and if my shares were in an ISA then I'd have thought about doing it but as they're not I can't. Makes the broker targets worthless really. Be interesting to see if any decided to reduce their target prices.
Buy on rumour, sell on news....
Simplifying the tax arrangements to match other Internet giants in Ireland. ;O)
If people don't believe what bonum says then do they also disbelieve what dweill has to say about TLDH?
Agreed. Annoying about the criticism of bonum's figures as he has always stressed that he uses figures on the conservative side in his valuations. Anyway I know who I'm more inclined to pay attention to.....